FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016058650> ?p ?o ?g. }

• W3016058650 endingPage "4068" @default.
• W3016058650 startingPage "4059" @default.
• W3016058650 abstract "Abstract Background The Response Evaluation Criteria in Solid Tumors (RECIST) for computed tomography (CT) is preoperatively used to evaluate therapeutic effects. However, it does not reflect the pathological treatment response (PTR) of pancreatic ductal adenocarcinoma (PDAC). The Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) for positron emission tomography (PET)/CT is effective in other cancers. This study aimed to confirm the usefulness of PERCIST and the prognostic utility of PET/CT for PDAC. Methods Forty‐two consecutive patients with PDAC who underwent neoadjuvant therapy (NAT) and pancreatectomy at our institution between 2014 and 2018 were retrospectively analyzed. We evaluated the treatment response and prognostic significance of PET/CT parameters and other clinicopathological factors. Results Twenty‐two patients who underwent PET/CT both before and after NAT with the same protocol were included. RECIST revealed stable disease and partial response in 20 and 2 cases, respectively. PERCIST revealed stable metabolic disease, partial metabolic response, and complete metabolic response in 8, 9, and 5 cases, respectively. The PTR was G3, G2, and G1 in 8, 12, and 2 cases, respectively. For comparing the concordance rates between PTR and each parameter, PERCIST (72.7% [16/22]) was significantly superior to RECIST (36.4% [8/22]) ( P = .017). The area under the curve survival values of PET/CT parameters were 0.777 for metabolic tumor volume (MTV), 0.500 for maximum standardized uptake value, 0.554 for peak standardized uptake value corrected for lean body mass, and 0.634 for total lesion glycolysis. A 50% cut‐off value for the MTV reduction rate yielded the largest difference in survival between responders and nonresponders. On multivariate analysis, MTV reduction rates < 50% were independent predictors for relapse‐free survival (hazard ratio [HR], 3.92; P = .044) and overall survival (HR, 14.08; P = .023). Conclusions PERCIST was more accurate in determining NAT’s therapeutic effects for PDAC than RECIST. MTV reduction rates were independent prognostic factors for PDAC." @default.
• W3016058650 created "2020-04-17" @default.
• W3016058650 creator A5003438742 @default.
• W3016058650 creator A5014273795 @default.
• W3016058650 creator A5014718861 @default.
• W3016058650 creator A5018112691 @default.
• W3016058650 creator A5020594980 @default.
• W3016058650 creator A5034596073 @default.
• W3016058650 creator A5041646818 @default.
• W3016058650 creator A5056642819 @default.
• W3016058650 creator A5058735880 @default.
• W3016058650 creator A5075592006 @default.
• W3016058650 creator A5078931094 @default.
• W3016058650 creator A5079301585 @default.
• W3016058650 creator A5082561795 @default.
• W3016058650 creator A5083594474 @default.
• W3016058650 creator A5084039755 @default.
• W3016058650 creator A5084368743 @default.
• W3016058650 creator A5087264886 @default.
• W3016058650 creator A5087879532 @default.
• W3016058650 date "2020-04-12" @default.
• W3016058650 modified "2023-10-14" @default.
• W3016058650 title "Usefulness of ¹⁸F‐fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma" @default.
• W3016058650 cites W1981989535 @default.
• W3016058650 cites W1990383064 @default.
• W3016058650 cites W1994177577 @default.
• W3016058650 cites W2005999920 @default.
• W3016058650 cites W2019607817 @default.
• W3016058650 cites W2024418047 @default.
• W3016058650 cites W2029774946 @default.
• W3016058650 cites W2036315064 @default.
• W3016058650 cites W2059833030 @default.
• W3016058650 cites W2099329725 @default.
• W3016058650 cites W2110799061 @default.
• W3016058650 cites W2155263737 @default.
• W3016058650 cites W2342772669 @default.
• W3016058650 cites W2412717755 @default.
• W3016058650 cites W2549878845 @default.
• W3016058650 cites W2713142620 @default.
• W3016058650 cites W2735284619 @default.
• W3016058650 cites W2743061229 @default.
• W3016058650 cites W2756109015 @default.
• W3016058650 cites W2771634364 @default.
• W3016058650 cites W2799951058 @default.
• W3016058650 cites W2800090167 @default.
• W3016058650 cites W2884956786 @default.
• W3016058650 cites W2895756706 @default.
• W3016058650 cites W2967269550 @default.
• W3016058650 cites W2987227731 @default.
• W3016058650 cites W575655861 @default.
• W3016058650 cites W824762829 @default.
• W3016058650 doi "https://doi.org/10.1002/cam4.3044" @default.
• W3016058650 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7300404" @default.
• W3016058650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32281301" @default.
• W3016058650 hasPublicationYear "2020" @default.
• W3016058650 type Work @default.
• W3016058650 sameAs 3016058650 @default.
• W3016058650 citedByCount "20" @default.
• W3016058650 countsByYear W30160586502021 @default.
• W3016058650 countsByYear W30160586502022 @default.
• W3016058650 countsByYear W30160586502023 @default.
• W3016058650 crossrefType "journal-article" @default.
• W3016058650 hasAuthorship W3016058650A5003438742 @default.
• W3016058650 hasAuthorship W3016058650A5014273795 @default.
• W3016058650 hasAuthorship W3016058650A5014718861 @default.
• W3016058650 hasAuthorship W3016058650A5018112691 @default.
• W3016058650 hasAuthorship W3016058650A5020594980 @default.
• W3016058650 hasAuthorship W3016058650A5034596073 @default.
• W3016058650 hasAuthorship W3016058650A5041646818 @default.
• W3016058650 hasAuthorship W3016058650A5056642819 @default.
• W3016058650 hasAuthorship W3016058650A5058735880 @default.
• W3016058650 hasAuthorship W3016058650A5075592006 @default.
• W3016058650 hasAuthorship W3016058650A5078931094 @default.
• W3016058650 hasAuthorship W3016058650A5079301585 @default.
• W3016058650 hasAuthorship W3016058650A5082561795 @default.
• W3016058650 hasAuthorship W3016058650A5083594474 @default.
• W3016058650 hasAuthorship W3016058650A5084039755 @default.
• W3016058650 hasAuthorship W3016058650A5084368743 @default.
• W3016058650 hasAuthorship W3016058650A5087264886 @default.
• W3016058650 hasAuthorship W3016058650A5087879532 @default.
• W3016058650 hasBestOaLocation W30160586501 @default.
• W3016058650 hasConcept C121608353 @default.
• W3016058650 hasConcept C126322002 @default.
• W3016058650 hasConcept C126838900 @default.
• W3016058650 hasConcept C160798450 @default.
• W3016058650 hasConcept C199374082 @default.
• W3016058650 hasConcept C2775842073 @default.
• W3016058650 hasConcept C2776694085 @default.
• W3016058650 hasConcept C2778292576 @default.
• W3016058650 hasConcept C2778822529 @default.
• W3016058650 hasConcept C2779984678 @default.
• W3016058650 hasConcept C2781182431 @default.
• W3016058650 hasConcept C2989005 @default.
• W3016058650 hasConcept C530470458 @default.
• W3016058650 hasConcept C71924100 @default.
• W3016058650 hasConceptScore W3016058650C121608353 @default.
• W3016058650 hasConceptScore W3016058650C126322002 @default.
• W3016058650 hasConceptScore W3016058650C126838900 @default.

• next